Jennie P. Mather, Ph.D.

Dr. Mather joined Genentech in 1984, where she was a major contributor to 8 of Genentech’s marketed products including Herceptin and Avastin. Dr. Mather founded Raven biotechnologies in 1999. Raven was acquired by MacroGenics in 2008 after raising a cumulative $112 million and a successful phase I study. Dr. Mather is providing her extensive experience in cell line development and biologics R&D to the PTM Therapeutics team.

Leonard G. Presta, Ph.D.

Dr. Presta has more than 30 years of experience in the biotechnology industry, primarily in protein/antibody engineering. Dr. Presta joined Genentech in 1988, where he was responsible for the protein engineering that led to marketed therapeutic monoclonal antibodies Herceptin, Raptiva, Xolair, Avastin, Lucentis, Perjeta, Ocrevus, and therapeutic protein Tenecteplase. Dr. Presta was also responsible for engineering the Merck therapeutic antibody Ilumya. Dr. Presta is an inventor on 160 issued U.S. patents, and served on the editorial board for Journal of Biological Chemistry, PROTEINS, and MABS. Dr. Presta is assisting PTM Therapeutics with his vast biologics engineering and development experience.

Sarah Bodary, Ph.D.

Dr. Bodary has more than 30 years of experience in biotechnology business and drug development as well as company creation and venture investing. She led the sale of the anti-TIGIT antibody from Abmuno Therapeutics to Arcus Biosciences. She was Vice President of Business Development at Cellular Research, Inc., (acquired by Becton Dickinson) and led deals in Oncology and Immunology at the Johnson and Johnson Innovation Center. Dr. Bodary was a member of the therapeutic investing team while a Venture Partner at SV Life Sciences, and served on the board of Itero Biopharmaceuticals. Dr. Bodary was a member of the management team at Schering Plough Biopharma as a Director of Business and Product Development, where she helped transform DNAX Research Institute into the discovery engine for Schering Plough and managed the biologics business development efforts. At Genentech, where she was a Senior Scientist, Dr. Bodary led therapeutic product teams targeting Integrins, three of which progressed from target identification through Phase 1, and was a member of the Raptiva late stage development, BLA filing and launch teams. She is an author on numerous peer reviewed journals and an inventor on over 30 patents.

Asma Nusrat, M.D.

Dr. Nusrat is the F. Peyton Rous Professor and Director of Experimental Pathology at the University of Michigan. Trained in Anatomic Pathology and epithelial biology at the Brigham and Women’s Hospital (BWH)/Harvard Medical School, she began investigating fundamental mechanisms of epithelial barrier regulation and mucosal wound repair as a faculty member from 1992-1997 at the same institution. Dr. Nusrat moved to Emory University and rose to the rank of Tenured Professor (1997 to 2015). She subsequently joined the University of Michigan in her current capacity in 2015. Dr. Nusrat continues to study and lead the field in epithelial barrier regulation and mucosal wound repair, and has published more than 200 scientific manuscripts on the subject. Dr. Nusrat continues to serve on a number of editorial boards and grant review study sections.